Upregulation of IL‐1R2 has been observed in different cancers, such as pancreatic ductal adenocarcinoma (Rückert et al., 2010), prostate cancer (Ricote et al., 2010), and ovarian cancer (Laios et al., 2008), supporting the involvement of IL‐1R2 in cancer progression. This evidence concerns the gene IL1R2 and prostate carcinoma.